Professional Documents
Culture Documents
By
Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland
July 2012
AUTHOR'S
BIOGRAPHY
ABOUT
THIS
REPORT
+4161-6924461
info@pharmabiotech.ch
http://pharmabiotech.ch/
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted
in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written
permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the
consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information
presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.
-2-
TABLE
OF
CONTENTS
-3-
-4-
-5-
-6-
-7-
Gene knockout and gene suppression for validating protein targets ...................................... 178
Laser-mediated protein knockout for target validation ........................................................ 178
Integrated proteomics for drug discovery........................................................................ 178
High-throughput proteomics ............................................................................................ 179
Companies involved in high-throughput proteomics ............................................................ 179
Drug discovery through protein-protein interaction studies ............................................ 180
Protein-protein interaction as basis for drug target identification .......................................... 180
Protein-PCNA interaction as basis for drug design .............................................................. 181
Two-hybrid protein interaction technology for target identification........................................ 181
Biosensors for detection of small molecule-protein interactions ............................................ 182
Protein-protein interaction maps ...................................................................................... 183
ProNet (Myriad Genetics) ........................................................................................... 183
Hybrigenics' maps of protein-protein interactions .......................................................... 183
CellZome's functional map of protein-protein interactions .............................................. 183
Mapping of protein-protein interactions by mass spectrometry............................................. 184
Protein interaction map of Drosophila melanogaster ........................................................... 184
Protein-interaction map of Wellcome Trust Sanger Institute ................................................ 185
Protein-protein interactions as targets for therapeutic intervention ....................................... 185
Inhibition of protein-protein interactions by peptide aptamers ............................................. 185
Selective disruption of proteins by small molecules ............................................................ 186
Post-genomic combinatorial biology approach................................................................. 186
Differential proteomics .................................................................................................... 186
Shotgun proteomics ......................................................................................................... 187
Chemogenomics/chemoproteomics for drug discovery .................................................... 188
Chemoproteomics-based drug discovery ...................................................................... 189
Companies involved in chemogenomics/chemoproteomics .............................................. 190
Activity-based proteomics .......................................................................................... 191
Locus Discovery technology ........................................................................................ 191
Automated ligand identification system ........................................................................ 192
Expression proteomics: protein level quantification ........................................................ 192
Role of phage antibody libraries in target discovery ........................................................ 193
Analysis of posttranslational modification of proteins by MS ........................................... 193
Phosphoproteomics for drug discovery ............................................................................ 194
Application of glycoproteomics for drug discovery........................................................... 194
Role of carbohydrates in proteomics ................................................................................. 194
Challenges of glycoproteomics ......................................................................................... 195
Companies involved in glycoproteomics ............................................................................ 195
Role of protein microarrays/ biochips for drug discovery ................................................ 196
Protein microarrays vs DNA microarrays for high-throughput screening ................................ 196
BIA-MS biochip for protein-protein interactions .................................................................. 196
ProteinChip with Surface Enhanced Neat Desorption ........................................................... 197
Protein-domains microarrays ........................................................................................... 197
Some limitations of protein biochips ................................................................................. 197
Concluding remarks about role of proteomics in drug discovery ...................................... 198
RNA versus protein profiling as guide to drug development ............................................ 198
RNA as drug target......................................................................................................... 198
Combination of RNA and protein profiling .......................................................................... 199
RNA binding proteins ................................................................................................. 200
Toxicoproteomics ............................................................................................................. 200
Hepatotoxicity ............................................................................................................... 200
Nephrotoxicity ............................................................................................................... 201
Cardiotoxicity ................................................................................................................ 201
Neurotoxicity ................................................................................................................. 202
Protein/peptide therapeutics ........................................................................................... 202
Peptide-based drugs ....................................................................................................... 202
Phylomer peptides ........................................................................................................ 203
Cryptein-based therapeutics ............................................................................................ 203
Synthetic proteins and peptides as pharmaceuticals ........................................................... 204
Genetic immunization and proteomics ............................................................................. 204
Proteomics and gene therapy .......................................................................................... 205
Role of proteomics in clinical drug development .............................................................. 205
Pharmacoproteomics ...................................................................................................... 205
Role of proteomics in clinical drug safety........................................................................... 206
-8-
-9-
- 10 -
10.
11.
Introduction..................................................................................................................... 281
Potential markets for proteomic technologies ................................................................. 281
Bioinformatics markets for proteomics .............................................................................. 282
Markets for protein separation technologies....................................................................... 282
Markets for 2D gel electrophoresis .............................................................................. 282
Market trends in protein separation technolgies ............................................................ 283
Protein purification markets............................................................................................. 283
Mass spectrometry markets............................................................................................. 283
Markets for MALDI for drug discovery ............................................................................... 284
Markets for nuclear magnetic resonance spectroscopy ........................................................ 284
Market for structure-based drug design ............................................................................ 284
Markets for protein biomarkers ........................................................................................ 285
Markets for cell-based protein assays ............................................................................... 285
Protein biochip markets .................................................................................................. 285
Western blot markets ..................................................................................................... 285
Geographical distribution of proteomics technologies markets.............................................. 286
Business and strategic considerations ............................................................................. 286
Cost of protein structure determination............................................................................. 286
Opinion surveys of the scientist consumers of proteomic technologies .................................. 286
Opinions on mass spectrometry .................................................................................. 286
Opinions on bioinformatics and proteomic databases ..................................................... 287
Systems for in vivo study of protein-protein interactions ................................................ 287
Perceptions of the value of protein biochip/microfluidic systems ...................................... 287
Small versus big companies ............................................................................................ 287
Expansion in proteomics according to area of application .................................................... 288
Growth trends in cell-based protein assay market .............................................................. 288
Challenges for development of cell-based protein assays................................................ 288
Future trends and prospects of cell-based protein assays ............................................... 289
Strategic collaborations .................................................................................................. 289
Analysis of proteomics collaborations according to types of companies............................. 289
Types of proteomic collaborations ............................................................................... 290
Proteomics collaborations according to application areas ................................................ 290
Analysis of proteomics collaborations: types of technologies ........................................... 291
Collaborations based on protein biochip technology ....................................................... 291
Concluding remarks about proteomic collaborations ...................................................... 292
Proteomic patents .......................................................................................................... 292
Market drivers in proteomics ........................................................................................... 293
Needs of the pharmaceutical industry ............................................................................... 293
Need for outsourcing proteomic technologies ..................................................................... 293
Funding of proteomic companies and research ................................................................... 293
Technical advances in proteomics .................................................................................... 294
Changing trends in healthcare in future ............................................................................ 294
Challenges facing proteomics .......................................................................................... 294
Magnitude and complexity of the task ............................................................................... 294
Technical challenges ....................................................................................................... 295
Limitations of proteomics ................................................................................................ 295
Limitations of 2DGE ................................................................................................... 295
Limitations of mass spectrometry techniques ................................................................ 295
Complexity of the pharmaceutical proteomics ............................................................... 296
Unmet needs in proteomics ............................................................................................. 296
- 11 -
12.
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
1-1:
1-2:
1-3:
1-4:
2-1:
2-2:
2-3:
2-4:
2-5:
2-6:
2-7:
2-8:
3-1:
3-2:
4-1:
4-2:
4-3:
4-4:
5-1:
5-2:
6-1:
6-2:
6-3:
6-4:
6-5:
6-6:
6-7:
- 12 -
Table
Table
Table
Table
Table
Table
Table
Table
Table
Figures
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
- 13 -